Eris和Natco将于2026年3月在印度上市仿制司美格鲁肽，专利到期后。 Eris and Natco to launch generic semaglutide in India in March 2026 post-patent expiry.

Eris Lifesciences与Natco Pharma合作，在印度商业化一款仿制药semaglutide，计划在获得监管批准后于2026年3月上市。 Eris Lifesciences has teamed with Natco Pharma to commercialize a generic version of semaglutide in India, with a planned launch in March 2026 following regulatory approval. 在印度,用于治疗糖尿病和肥胖症的药物专利到期后,该药的专利即告到期。 The move comes as the patent for the drug, used to treat diabetes and obesity, expires in India. 该伙伴关系将Eris的商业实力和糖尿病专业知识与Natco的制造和监管能力相结合。 The partnership combines Eris’s commercial strength and diabetes expertise with Natco’s manufacturing and regulatory capabilities. 一些印度公司正准备进入市场,这标志着向更广泛获得代谢性疾病治疗的转变。 Several Indian firms are preparing to enter the market, signaling a shift toward broader access to metabolic disease treatments.